<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433900</url>
  </required_header>
  <id_info>
    <org_study_id>MSD-007</org_study_id>
    <nct_id>NCT01433900</nct_id>
  </id_info>
  <brief_title>Switching From Preserved to Preserved-free Treatments for Glaucoma.</brief_title>
  <official_title>The Advantage of Switching From Preserved to Preserved-free Treatments in Glaucoma. A Clinical and Confocal Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paolo Fogagnolo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 1-year prospective, randomized, investigator-masked trial comparing the confocal and&#xD;
      clinical effects of treatment with unpreserved prostaglandins (tafluprost) versus preserved&#xD;
      prostaglandins (latanoprost) in newly-diagnosed glaucoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study protocol comprises 5 visits: baseline, month 3, month 6, month 9, month 12.&#xD;
&#xD;
      At baseline a clinical evaluator will perform a complete ophthalmologic evaluation to confirm&#xD;
      diagnosis. The following examinations will be done in the following sequence: anterior&#xD;
      segment examination, Shirmer test, Break-up time test. Thereafter, a confocal evaluator will&#xD;
      perform confocal microscopy of the central and the peripheral cornea. Finally, contact&#xD;
      measurements will be done in the following order: IOP (which will be measured at 3 pm),&#xD;
      pachimetry (only at baseline visit) and gonioscony (only at baseline visit). A 15 minutes&#xD;
      interval will elapse between two consecutive tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the difference in the fiber density of the subbasal nerves in the central cornea and in each of 4 limbal quadrants</measure>
    <time_frame>Month 3, 6, 9, 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in sub-basal nerve characteristics (reflectivity, beading, tortuosity)</measure>
    <time_frame>Months 3, 6, 9 ,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in density of epithelial cells, Langerhans cells, endothelial cells</measure>
    <time_frame>Month 3, 6, 9 ,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ocular surface (symptom and sign scales, break-up time, Schirmer test)</measure>
    <time_frame>Month 3, 6, 9, 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Tafluprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop of latanoprost to eligible eye(s) once daily (at 9 pm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafluprost</intervention_name>
    <description>1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)</description>
    <arm_group_label>Tafluprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)</description>
    <arm_group_label>Latanoprost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient is suffering from ocular hypertension, POAG, PEX, NTG. Glaucoma definition&#xD;
             is based on the European Glaucoma Society Guidelines.&#xD;
&#xD;
          -  The patient is newly-diagnosed&#xD;
&#xD;
          -  No fluorescein staining at baseline and no observable signs of ocular surface disease&#xD;
&#xD;
          -  No treatment with topical BAK-containing products for at least 6 months&#xD;
&#xD;
          -  Treatment of na√Øve patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to sign informed consent&#xD;
&#xD;
          -  Not at least 18 years old&#xD;
&#xD;
          -  Ocular condition that are of safety concern and that can interfere with the study&#xD;
             results&#xD;
&#xD;
          -  Closed/barely open anterior chamber angles or history of acute angle closure.&#xD;
&#xD;
          -  Ocular surgery or argon laser trabeculoplasty within the last year. Ocular&#xD;
             inflammation/infection occurring within three months prior to pre-trial visit.&#xD;
&#xD;
          -  Presence of the following ocular conditions: KCS, moderate-severe blepharitis,&#xD;
             Rosacea, Sjogren syndrome, pterygium, contact lens users.&#xD;
&#xD;
          -  Use of concomitant topical ocular medication that can interfere with study medication&#xD;
&#xD;
          -  Hypersensitivity to benzalkonium chloride or to any other component of the trial drug&#xD;
             solutions.&#xD;
&#xD;
          -  Any corneal pathology&#xD;
&#xD;
          -  Diabetes at any stage&#xD;
&#xD;
          -  Other abnormal condition or symptom preventing the patient from entering the trial,&#xD;
             according to the Investigator's judgement.&#xD;
&#xD;
          -  Refractive surgery patients&#xD;
&#xD;
          -  Women who are pregnant, are of childbearing potential and are not using adequate&#xD;
             contraception or are nursing.&#xD;
&#xD;
          -  Inability to adhere to treatment/visit plan.&#xD;
&#xD;
          -  Have participated in any other clinical trial (i.e., requiring informed consent)&#xD;
             within one to three month prior to pre-trial visit (depending on ethics committee&#xD;
             decisions).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Rossetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Paolo Hospital, Milan, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luca Rossetti, MD</last_name>
    <phone>+390281844401</phone>
    <email>luca.rossetti@unimi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Paolo Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luca Rossetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Fogagnolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Paolo Fogagnolo</investigator_full_name>
    <investigator_title>Prof. Luca Rossetti</investigator_title>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>intraocular pressure</keyword>
  <keyword>ocular surface</keyword>
  <keyword>benzalkonium chloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

